E

Erasca
D

ERAS

15.115
USD
1.01
(7.12%)
مغلق
حجم التداول
108,489
الربح لكل سهم
-0
العائد الربحي
-
P/E
-35
حجم السوق
4,679,404,558
المقالات

العنوان: Erasca

القطاع: Healthcare
الصناعة: Biotechnology
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib,a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.